Androgen hypersensitivity in prostate cancer: molecular perspectives on androgen deprivation therapy strategies

Area of Science:

• Oncology
• Biochemistry
• Endocrinology

Background:

• Advanced prostate cancer often becomes resistant to androgen deprivation therapy (ADT).
• Understanding the mechanisms of hormone resistance is critical for improving treatment outcomes.
• Tumor recurrence after ADT necessitates novel therapeutic strategies.

Purpose of the Study:

• To review preclinical evidence for androgen hypersensitivity (AH) as a mechanism of hormone resistance in prostate cancer.
• To propose that some hormone-refractory (HR) tumors may be hypersensitive to androgens.
• To explore the potential clinical implications of AH for treatment strategies.

Main Methods:

• Review of preclinical studies investigating androgen hypersensitivity.
• Analysis of proposed mechanisms for tumor growth and dependence on low hormone levels.
• Exploration of potential therapeutic interventions targeting AH.

Main Results:

• Preclinical evidence suggests androgen hypersensitivity (AH) as a mechanism for developing hormone-refractory (HR) prostate cancer.
• Some HR tumors may grow in response to low androgen levels and be inhibited by normal levels.
• AH may identify a subset of prostate cancer patients amenable to specific intermittent therapies.

Conclusions:

• Androgen hypersensitivity is a potential mechanism driving prostate cancer recurrence after ADT.
• Further investigation of AH in preclinical and clinical settings is warranted.
• Biomarkers to identify patients with AH could guide personalized treatment strategies, including intermittent androgen withdrawal or testosterone replacement.